Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 24, 2021 07:35 ET | Source: Centogene NV

CENTOGENE Reports Third Quarter 2021 Financial Results

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
November 18, 2021 06:30 ET | Source: Centogene NV

CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
November 04, 2021 06:30 ET | Source: Centogene NV

CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases

CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
October 28, 2021 06:30 ET | Source: Centogene NV

CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study

FTD is a rapidly progressing neurodegenerative disease; up to 30% of all cases worldwide caused by genetic mutations, including the progranulin gene mutation (FTD-GRN)Study will enroll and genetically...
October 06, 2021 08:00 ET | Source: CENTOGENE GmbH

CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating...
September 29, 2021 17:05 ET | Source: CENTOGENE GmbH

CENTOGENE’s Ground-Breaking Family Genetic Research Published in the New England Journal of Medicine Reveals Path to Potential Cure for Structural Birth Defects

Collaborative research utilized insights gained from CENTOGENE’s rare disease-centric Bio/Databank to help analyze data of more than 20,000 familiesEnabled testing of successful targeted therapeutic...
September 07, 2021 06:35 ET | Source: CENTOGENE GmbH

CENTOGENE Reports Second Quarter 2021 Financial Results

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
September 01, 2021 06:30 ET | Source: CENTOGENE GmbH

CENTOGENE to Announce Second Quarter 2021 Financial Results on September 7, 2021

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
July 27, 2021 06:30 ET | Source: CENTOGENE GmbH

CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
June 25, 2021 06:30 ET | Source: CENTOGENE GmbH

CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right